(PEN) Penumbra - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 12.786m USD | Total Return: 16.5% in 12m
Thrombectomy Systems, Embolization Coils, Access Catheters, Neurosurgical Tools
Total Rating 57
Safety 92
Buy Signal -0.11
Medical Devices
Industry Rotation: +4.2
Industry Rotation: +4.2
Market Cap:
12.8B
Avg Turnover: 141M
Avg Turnover: 141M
Risk 3d forecast
Volatility10.8%
VaR 5th Pctl1.69%
VaR vs Median-5.45%
Reward TTM
Sharpe Ratio0.49
Rel. Str. IBD53.8
Rel. Str. Peer Group66.9
Character TTM
Beta0.609
Beta Downside0.544
Hurst Exponent0.518
Drawdowns 3y
Max DD52.44%
CAGR/Max DD0.04
CAGR/Mean DD0.08
EPS (Earnings per Share)
EPS CAGR: 58.30%
EPS Trend: 90.9%
EPS Trend: 90.9%
Last SUE: -1.92
Qual. Beats: -1
Qual. Beats: -1
Revenue
Rev. CAGR: 16.00%
Rev. Trend: 99.5%
Rev. Trend: 99.5%
Last SUE: 0.48
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: PEN Penumbra
Penumbra, Inc. is a medical technology company specializing in the design and manufacture of innovative devices for neurovascular and peripheral vascular conditions. The company’s core portfolio focuses on mechanical thrombectomy, utilizing computer-assisted vacuum technology and power aspiration systems to remove blood clots from the body. Beyond clot management, Penumbra develops embolization coils for treating aneurysms and neurosurgical tools for fluid and tissue evacuation.
The company operates within the high-barrier Health Care Equipment sector, where growth is largely driven by the adoption of minimally invasive procedures that reduce patient recovery times. Penumbra utilizes a direct sales model in major markets while leveraging third-party distributors internationally to scale its global footprint. For a deeper look at the fundamental metrics driving this business, consider reviewing the detailed reports on ValueRay.
- Market adoption of Lightning Flash and Lightning Bolt drives thrombectomy revenue growth
- Expansion of computer-assisted vacuum thrombectomy technology increases procedural volume and margins
- Market share gains in neurovascular and peripheral segments offset competitive pricing pressures
- R&D investment and product launch cycles influence operating margin and profitability targets
Piotroski VR‑10 (Strict)
7.0
| Net Income: 171.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 1.77 > 1.0 |
| NWC/Revenue: 73.14% < 20% (prev 67.82%; Δ 5.32% < -1%) |
| CFO/TA 0.15 > 3% & CFO 276.7m > Net Income 171.0m |
| Net Debt (-25.1m) to EBITDA (212.6m): -0.12 < 3 |
| Current Ratio: 6.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.5m) vs 12m ago 0.97% < -2% |
| Gross Margin: 67.38% > 18% (prev 0.64%; Δ 6.67k% > 0.5%) |
| Asset Turnover: 83.30% > 50% (prev 77.83%; Δ 5.47% > 0%) |
| Interest Coverage Ratio: 123.9 > 6 (EBITDA TTM 212.6m / Interest Expense TTM 1.31m) |
Altman Z''
5.44
| A: 0.56 (Total Current Assets 1.28b - Total Current Liabilities 211.7m) / Total Assets 1.90b |
| B: 0.14 (Retained Earnings 270.3m / Total Assets 1.90b) |
| C: 0.09 (EBIT TTM 161.9m / Avg Total Assets 1.75b) |
| D: 0.64 (Book Value of Equity 272.4m / Total Liabilities 424.6m) |
| Altman-Z'' Score: 5.44 = AAA |
Beneish M
-3.20
| DSRI: 0.93 (Receivables 183.3m/168.0m, Revenue 1.45b/1.24b) |
| GMI: 0.95 (GM 67.38% / 63.68%) |
| AQI: 0.77 (AQ_t 0.15 / AQ_t-1 0.20) |
| SGI: 1.17 (Revenue 1.45b / 1.24b) |
| TATA: -0.06 (NI 171.0m - CFO 276.7m) / TA 1.90b) |
| Beneish M-Score: -3.20 (Cap -4..+1) = AA |
What is the price of PEN shares?
As of May 21, 2026, the stock is trading at USD 327.38 with a total of 448,798 shares traded.
Over the past week, the price has changed by +1.48%, over one month by -0.71%, over three months by -3.53% and over the past year by +16.45%.
Over the past week, the price has changed by +1.48%, over one month by -0.71%, over three months by -3.53% and over the past year by +16.45%.
Is PEN a buy, sell or hold?
Penumbra has received a consensus analysts rating of 4.44.
Therefore, it is recommended to buy PEN.
- StrongBuy: 12
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PEN price?
| Analysts Target Price | 363.4 | 11% |
Penumbra (PEN) - Fundamental Data Overview
as of 19 May 2026
P/E Trailing = 74.731 P/E Forward = 63.6943
P/S = 8.7919
P/B = 8.5993
P/EG = 0.7435
Revenue TTM = 1.45b USD
EBIT TTM = 161.9m USD
EBITDA TTM = 212.6m USD
Long Term Debt = 20.7m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 216.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -25.1m USD (from netDebt column, last quarter)
Enterprise Value = 12.76b USD (12.79b + Debt 216.2m - CCE 241.3m)
Interest Coverage Ratio = 123.9 (Ebit TTM 161.9m / Interest Expense TTM 1.31m)
EV/FCF = 59.99x (Enterprise Value 12.76b / FCF TTM 212.7m)
FCF Yield = 1.67% (FCF TTM 212.7m / Enterprise Value 12.76b)
FCF Margin = 14.63% (FCF TTM 212.7m / Revenue TTM 1.45b)
Net Margin = 11.76% (Net Income TTM 171.0m / Revenue TTM 1.45b)
Gross Margin = 67.38% ((Revenue TTM 1.45b - Cost of Revenue TTM 474.3m) / Revenue TTM)
Gross Margin QoQ = 67.62% (prev 68.02%)
Tobins Q-Ratio = 6.72 (Enterprise Value 12.76b / Total Assets 1.90b)
Interest Expense / Debt = 0.15% (Interest Expense 317k / Debt 216.2m)
Taxrate = 21.84% (9.10m / 41.7m)
NOPAT = 126.6m (EBIT 161.9m * (1 - 21.84%))
Current Ratio = 6.02 (Total Current Assets 1.28b / Total Current Liabilities 211.7m)
Debt / Equity = 0.15 (Debt 216.2m / totalStockholderEquity, last quarter 1.47b)
Debt / EBITDA = -0.12 (Net Debt -25.1m / EBITDA 212.6m)
Debt / FCF = -0.12 (Net Debt -25.1m / FCF TTM 212.7m)
Total Stockholder Equity = 1.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.80% (Net Income 171.0m / Total Assets 1.90b)
RoE = 12.32% (Net Income TTM 171.0m / Total Stockholder Equity 1.39b)
RoCE = 11.49% (EBIT 161.9m / Capital Employed (Equity 1.39b + L.T.Debt 20.7m))
RoIC = 9.11% (NOPAT 126.6m / Invested Capital 1.39b)
WACC = 7.99% (E(12.79b)/V(13.00b) * Re(8.12%) + D(216.2m)/V(13.00b) * Rd(0.15%) * (1-Tc(0.22)))
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 37.78 | Cagr: 0.29%
[DCF] Terminal Value 81.63% ; FCFF base≈187.8m ; Y1≈231.6m ; Y5≈395.2m
[DCF] Fair Price = 173.8 (EV 6.81b - Net Debt -25.1m = Equity 6.83b / Shares 39.3m; r=7.99% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 90.85 | EPS CAGR: 58.30% | SUE: -1.92 | # QB: -1
Revenue Correlation: 99.48 | Revenue CAGR: 16.00% | SUE: 0.48 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.14 | Chg30d=-3.93% | Revisions=-50% | Analysts=8
EPS next Quarter (2026-09-30): EPS=1.27 | Chg30d=-2.47% | Revisions=-50% | Analysts=8
EPS current Year (2026-12-31): EPS=4.89 | Chg30d=-2.81% | Revisions=-43% | GrowthEPS=+27.5% | GrowthRev=+14.3%
EPS next Year (2027-12-31): EPS=6.30 | Chg30d=-1.33% | Revisions=-50% | GrowthEPS=+28.6% | GrowthRev=+12.3%
[Analyst] Revisions Ratio: -50%